Business
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to Health Canada for Medical Device License
(TheNewswire) VMS+4.0 submitted to Health Canada on July 25th for Medical Device Licens...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to Health Canada for Medical Device License\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n VMS+4.0 submitted to Health Canada on\nJuly 25th for Medical Device License\n \n\n\n\n\n\n Ventripoint will market new advances\nfollowing Health Canada approval\n \n\n\n\n\n\n Toronto, Ontario –\n \n\n TheNewswire -\n \n\n August 12, 2024\n \n\n -\nVentripoint Diagnostics Ltd.\n \n\n (\"\n \n\n Ventripoint\n \n\n \" or\nthe \"\n \n\n Company\n \n\n \"), (TSXV:VPT; OTC:VPTDF)\n \n\n has\nreached another development milestone by submitting its next\ngeneration of software, VMS+4.0, to Health Canada for a Medical Device\nLicense to market the upgraded product in Canada.\n \n\n\n\n This latest advance of Ventripoint’s AI-powered\ntechnology, which rapidly processes ultrasound images of the heart to\ngenerate MRI-quality measurements of all four cardiac chambers, is\ndesigned to integrate into the workflow of hospitals, clinics and\ncaregivers.\n \n\n\n\n Upon issuance of the Medical Device License,\nVentripoint will market the new version of VMS+ to Canadian customers.\n \n\n “It has taken our team two years of research\nand development to reach this major milestone,” said Ventripoint\nPresident and CEO, Hugh MacNaught. “VMS+4.0 promises to become one\nof the simplest, cost effective, and non-invasive heart-imaging tools\nin the market.”\n \n\n\n\n Ventripoint submitted VMS+4.0 for licensing to Health\nCanada on July 25th as a new Class II Medical Device Application with\nsoftware and hardware updates and featuring diagnostic advances.\nVMS+3.0 has already received regulatory clearances from US-FDA, Health\nCanada, the United Kingdom (U.K.) and the European Union (E.U.) and is\nbeing used by leading hospitals in the U.S., E.U., U.K. and Canada.\n \n\n We are also pursuing regulatory clearance in\nother key markets such as the E.U., U.K and U.S.A. to make this newest\nversion of VMS+ available to the global community.\n \n\n\n\n About Ventripoint Diagnostics\nLtd.\n \n\n\n\n Ventripoint\n \n\n is an industry leader\nin the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary Knowledge Based Rec...